EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 26 / No 2 (Février 2010) Med Sci (Paris), 26 2 (2010) 115-118 References
Free Access
Editorial
Issue
Med Sci (Paris)
Volume 26, Number 2, Février 2010
Page(s) 115 - 118
Section Éditorial
DOI https://doi.org/10.1051/medsci/2010262115
Published online 15 February 2010
  1. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346 : 1185–93. [Google Scholar]
  2. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360 : 447–58. [Google Scholar]
  3. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12 : 401–9. [Google Scholar]
  4. Leboulch P and the LentiGlobin clinical trial study group. Conversion to transfusion independence with partial clonal dominance after lentiviral gene therapy for severe human beta-thalassemia (abstract). Hum Gene Ther 2009; 20 : 1369–70. [Google Scholar]
  5. Boztug K, Schmidt M, Schwarzer A, et al. HSC gene therapy in two WAS patients (abstract). Hum Gene Ther 2009; 20 : 1371. [Google Scholar]
  6. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006; 12 : 1397–402. [Google Scholar]
  7. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010 (sous presse). [Google Scholar]
  8. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326 : 818–23. [Google Scholar]
  9. Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. Blood 2009; 114 : 3524–32. [Google Scholar]
  10. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118 : 3132–42. [Google Scholar]
  11. Dykstra B, Kent D, Bowie M, et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 2007; 1 : 218–29. [Google Scholar]
  12. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364 : 2181–7. [Google Scholar]
  13. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118 : 3143–50. [Google Scholar]
  14. Kelly PF, Radtke S, von Kalle C, et al. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 2007; 15 : 211–9. [Google Scholar]
  15. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009; 15 : 285–92. [Google Scholar]
  16. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial) : a non-randomised phase I-II study. Lancet Oncol 2009; 10 : 489–500. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.